Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors.
Publication
, Journal Article
Crosby, EJ; Lyerly, HK; Hartman, ZC
Published in: Oncotarget
January 5, 2021
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Oncotarget
DOI
EISSN
1949-2553
Publication Date
January 5, 2021
Volume
12
Issue
1
Start / End Page
1 / 3
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Crosby, E. J., Lyerly, H. K., & Hartman, Z. C. (2021). Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors. Oncotarget, 12(1), 1–3. https://doi.org/10.18632/oncotarget.27861
Crosby, Erika J., H Kim Lyerly, and Zachary C. Hartman. “Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors.” Oncotarget 12, no. 1 (January 5, 2021): 1–3. https://doi.org/10.18632/oncotarget.27861.
Crosby EJ, Lyerly HK, Hartman ZC. Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors. Oncotarget. 2021 Jan 5;12(1):1–3.
Crosby, Erika J., et al. “Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors.” Oncotarget, vol. 12, no. 1, Jan. 2021, pp. 1–3. Pubmed, doi:10.18632/oncotarget.27861.
Crosby EJ, Lyerly HK, Hartman ZC. Cancer vaccines: the importance of targeting oncogenic drivers and the utility of combinations with immune checkpoint inhibitors. Oncotarget. 2021 Jan 5;12(1):1–3.
Published In
Oncotarget
DOI
EISSN
1949-2553
Publication Date
January 5, 2021
Volume
12
Issue
1
Start / End Page
1 / 3
Location
United States
Related Subject Headings
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis